Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Myeloid 1

Conditions

Breast Neoplasms 10Ovarian Neoplasms 9Fallopian Tube Neoplasms 8Triple Negative Breast Neoplasms 7Pancreatic Neoplasms 5Neoplasms 4Astrocytoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasm Metastasis 3Lymphoma 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Myeloid, Acute 3Glioblastoma 3Uterine Cervical Neoplasms 2Thrombocythemia, Essential 2Small Cell Lung Carcinoma 2Rectal Neoplasms 2Prostatic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Polycythemia Vera 2Medulloblastoma 2Lymphoma, Follicular 2Leukemia, Myelomonocytic, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hereditary Breast and Ovarian Cancer Syndrome 2Gliosarcoma 2Carcinoma, Non-Small-Cell Lung 2Burkitt Lymphoma 2Breast Neoplasms, Male 2Brain Neoplasms 2

Interventions

Cytarabine 33Etoposide 16Daunorubicin 16tipifarnib 10Mitoxantrone 10Idarubicin 9Azacitidine 8alvocidib 6Filgrastim 6Busulfan 6Peripheral Blood Stem Cell Transplantation 5valspodar 4Sorafenib 4Bortezomib 4fludarabine phosphate 3entinostat 3aldesleukin 3Vorinostat 3Tretinoin 3Radiotherapy 3Lenalidomide 3Gemtuzumab 3Decitabine 3Cyclophosphamide 3veliparib 2tanespimycin 2sargramostim 2lintuzumab 2laromustine 2Watchful Waiting 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Leukemia, Myelomonocytic, Acute × veliparib × Clear all
NCT01139970 2025-11-20

Veliparib and Temozolomide in Treating Patients With Acute Leukemia

National Cancer Institute (NCI)

Phase 1 Completed
66 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Leukemia, Myelomonocytic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT00588991 2025-04-02

Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders

National Cancer Institute (NCI)

Phase 1 Completed
12 enrolled
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Leukemia, Myelomonocytic, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡